SAFE Drugs Act of 2025
- Bill Number
- H.R. 6509
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-09: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-07-10T08:06:11Z
AI-Generated Summary
Purpose of the Legislation
The SAFE Drugs Act of 2025 aims to strengthen oversight of compounding pharmacies and outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). It seeks to prevent the widespread production of compounded drugs that mimic commercially available ones, ensure better tracking of interstate compounding, and enhance safety inspections and funding for these activities, ultimately protecting patients from potentially unsafe or fraudulent drug products.
Key Provisions
- Limits on Compounding Copies of Commercial Drugs (Section 2):
- Compounding pharmacies and physicians cannot compound a drug that is essentially a copy of a commercially available drug more than 20 times in a single month.
- Defines an "essentially a copy" as a drug with the same active ingredient as a commercial one, without a significant, patient-specific change (as determined by the prescribing doctor) that makes it clinically different.
- "Commercially available drug product" refers to drugs sold in the U.S. market from facilities meeting current good manufacturing practices and not listed as discontinued by the FDA.
- Reporting Requirements for Interstate Compounding (Section 3):
- For 2025 and beyond, pharmacies, facilities, or physicians that compound more than 20 times a month for out-of-state patients a drug containing an active ingredient from a commercial product must submit an annual report to the Secretary of Health and Human Services (who oversees the FDA).
- Reports must detail the types of drugs compounded and the total monthly counts for each.
- Reports are due by year-end, in a format specified by the FDA.
- Excludes compounding by hospital pharmacies for their own inpatients.
- Enhanced Inspections and Registration for Outsourcing Facilities (Section 4):
- Defines a "large-scale outsourcing facility" as one that compounds any drug more than 100 times in a calendar year.
- Requires FDA risk-based inspections, including an initial inspection before any compounding begins and reinspections at least every two years for large-scale facilities.
- Eliminates exemptions from FDA registration and reporting requirements for all outsourcing facilities.
- These changes take effect 6 months after the bill's enactment.
- Adjustment to Fees for Compounded Drug Oversight (Section 5):
- Replaces the fixed $15,000 base establishment fee for outsourcing facilities with an amount set by the FDA Secretary, based on what's needed to fund safety activities for compounded drugs.
Significant Changes to Existing Law
- Stricter Limits on Copying: Previously, compounding rules under Section 503A allowed more flexibility in copying commercial drugs; this bill caps it at 20 instances per month and adds precise definitions to prevent routine duplication without patient-specific justification.
- New Reporting Mandate: Introduces the first annual reporting obligation for high-volume interstate compounding of drugs with commercial ingredients, which did not exist before, to improve FDA tracking.
- Tougher Inspections: Expands FDA inspection requirements for outsourcing facilities (under Section 503B), mandating pre-operation checks and biennial reinspections for large-scale ones, beyond the prior risk-based schedule.
- End to Exemptions and Fee Flexibility: Removes registration exemptions for outsourcing facilities (under Section 510) and shifts from a fixed fee to a variable one tied to safety needs, allowing the FDA more adaptive funding.
Potential Impacts
- On Government Agencies: The FDA will face increased responsibilities for inspections, report processing, and fee-setting, potentially requiring more resources but supported by adjustable fees. This could lead to better enforcement of drug safety standards.
- On Citizens (Patients and Providers): Patients may benefit from safer compounded drugs due to reduced risks from unverified copies, but could face limited access to customized medications if pharmacies scale back to comply. Prescribing physicians and pharmacies might need to adjust practices, possibly increasing costs passed to consumers.
- On International Relations: Minimal direct impact, as the bill focuses on U.S.-based compounding and commercial drugs; however, it could indirectly affect global supply chains if stricter U.S. rules influence international compounding standards or exports.
Main Stakeholders Affected
- Compounding Pharmacies and Outsourcing Facilities: Primary targets, facing new limits, reporting duties, inspections, and fees, which could raise operational costs and compliance burdens.
- Physicians and Healthcare Providers: Must justify patient-specific changes for compounded drugs and may need to report if compounding exceeds thresholds.
- FDA and Federal Regulators: Gain tools for oversight but must implement new processes efficiently.
- Patients and Consumers: Indirectly affected through potentially safer drug options, though some may experience delays or shortages in personalized medications.
- Drug Manufacturers: Commercial producers might see reduced competition from compounded copies, potentially benefiting their market position.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Strengthens FDA authority under the FD&C Act without creating new agencies, but could lead to litigation if pharmacies challenge the 20-compound limit or definitions as overly restrictive on interstate commerce. The bill's definitions provide clearer guidelines, reducing ambiguity in enforcement.
- Constitutional Implications: Aligns with Congress's power to regulate interstate commerce and public health (under the Commerce Clause), with no apparent conflicts to free speech or due process; however, the reporting requirements might raise minor privacy concerns for patient data if not handled securely.
- Political Implications: Reflects bipartisan support (introduced by Reps. Yakym and Carson) for post-scandal reforms in compounding (e.g., referencing past contamination issues), potentially advancing public health priorities amid debates over drug access versus safety. It may influence future FDA funding debates by tying fees directly to oversight needs.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (17)
Rep. Carson, André [D-IN-7], Rep. McGuire, John J. [R-VA-5], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Moran, Nathaniel [R-TX-1], Rep. Ross, Deborah K. [D-NC-2], Rep. Miller, Carol D. [R-WV-1], Rep. Tenney, Claudia [R-NY-24], Rep. McDowell, Addison P. [R-NC-6], Rep. Bean, Aaron [R-FL-4], Rep. Kelly, Mike [R-PA-16], Rep. Baird, James R. [R-IN-4], Rep. Houchin, Erin [R-IN-9], Rep. Fong, Vince [R-CA-20], Rep. Shreve, Jefferson [R-IN-6], Rep. Messmer, Mark B. [R-IN-8], Rep. Edwards, Chuck [R-NC-11], Rep. Mrvan, Frank J. [D-IN-1]
Recent Actions
- 2025-12-09: Referred to the House Committee on Energy and Commerce.
- 2025-12-09: Introduced in House
- 2025-12-09: Introduced in House
Bill Versions
- Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025 — issued 2025-12-09 — PDF (6 pages)